{"id":858956,"date":"2025-06-10T08:37:34","date_gmt":"2025-06-10T12:37:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/"},"modified":"2025-06-10T08:37:34","modified_gmt":"2025-06-10T12:37:34","slug":"cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/","title":{"rendered":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities<\/em>\n      <\/p>\n<p>BOSTON, June  10, 2025  (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches.<\/p>\n<p>Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in\u00a0June 2025.\u00a0Dr. Verwijs\u00a0was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA and commercial launch. With a focus on drug product and process development, scale-up and validation, he has extensive expertise leading all CMC functions, including overseeing the supply chain and quality assurance. He has held leadership positions of increasing responsibility at several prominent Boston biotech companies including Aerovate, Epizyme, Flexion and Vertex.<\/p>\n<p>\u201cWe are pleased to welcome Dr. Verwijs to our leadership team as we embark on the next steps in the neflamapimod development pathway,\u201d said\u00a0John Alam, MD, Chief Executive Officer of CervoMed. \u201cWe believe that Marco will serve a pivotal function in assuring product quality as we advance neflamapimod into Phase 3 in dementia with Lewy Bodies (DLB) in mid-2026 and prepare for future regulatory filings and potential commercial launch. We look forward to leveraging his impressive skill set at this critical juncture for the Company as we prepare to initiate the Phase 3 pivotal trial in DLB.\u201d<\/p>\n<p>\n        <strong>Inducement Grants<\/strong><br \/>\n        <br \/>On\u00a0June 9, 2025, CervoMed granted Dr. Verwijs an option to purchase an aggregate of 54,000 shares of\u00a0CervoMed common stock with an exercise price of\u00a0$7.74, the closing price of the Company\u2019s common stock on the grant date. The option will vest in 36 equal installments on the last day of each month over a three-year period commencing June 30, 2025, subject to the employee\u2019s continued employment with the Company on each such date. The award was approved by the compensation committee of the Company\u2019s board of directors as an inducement material to Dr. Verwijs entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>\n        <strong>About CervoMed<\/strong><br \/>\n        <br \/>CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the Company\u2019s financial position and cash runway, the therapeutic potential of neflamapimod, the anticipated timing and achievement of clinical and development milestones, including the completion the RewinD-LB Phase 2b clinical trial and the Company\u2019s announcement of additional data therefrom, any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the AscenD-LB trial or RewinD-LB trial will be replicated in later trials, and the timing of the initiation of any potential future trials or interactions with regulatory authorities, including the Company\u2019s need to acquire sufficient funding prior to initiating any Phase 3 trial of neflamapimod in DLB. Terms such as \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201caims,\u201d \u201cseeks,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201ccontinue,\u201d or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company\u2019s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company\u2019s available cash resources and the availability of additional funds on acceptable terms; the results of the Company\u2019s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended\u00a0December 31, 2024\u00a0filed with the\u00a0U.S. Securities and Exchange Commission\u00a0(SEC) on\u00a0March 17, 2025, and other filings that the Company may file from time to time with the\u00a0SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.<\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>PJ Kelleher<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=abl9ltTn4bVPhdWvFsOb0RYXTjz_4ITi73C_WRrIGbw3w2O9EbBYrhcB-C7bJ_08VAoi1O_zlhBhflaHastwBSRsTh_EpBDml3q3pKh9m7A=\" rel=\"nofollow\" target=\"_blank\">Investors@cervomed.com<\/a><br \/>617-430-7579<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2JkODNlNTctMmNlYS00NDViLWFmOTMtMzQzM2IxZDg4MWViLTUwMDEyMTE2MC0yMDI1LTA2LTEwLWVu\/tiny\/CervoMed-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches. Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in\u00a0June 2025.\u00a0Dr. Verwijs\u00a0was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-858956","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches. Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in\u00a0June 2025.\u00a0Dr. Verwijs\u00a0was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA &hellip; Continue reading &quot;CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T12:37:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization\",\"datePublished\":\"2025-06-10T12:37:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/\"},\"wordCount\":910,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/\",\"name\":\"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\",\"datePublished\":\"2025-06-10T12:37:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/","og_locale":"en_US","og_type":"article","og_title":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk","og_description":"Strengthening CMC leadership to prepare for scaled up neflamapimod manufacturing On track to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities BOSTON, June 10, 2025 (GLOBE NEWSWIRE) &#8212; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported a key senior leadership hire to oversee the Company\u2019s Chemistry, Manufacturing, and Controls (CMC) division and advance the development of neflamapimod through Phase 3 testing and preparation of commercial batches. Marco Verwijs, PhD joined CervoMed as Executive Vice President, Technical Operations, in\u00a0June 2025.\u00a0Dr. Verwijs\u00a0was previously Chief Technical Officer at Adipo Therapeutics and has significant experience developing drugs, from the pre-clinical stage through NDA &hellip; Continue reading \"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T12:37:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization","datePublished":"2025-06-10T12:37:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/"},"wordCount":910,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/","name":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==","datePublished":"2025-06-10T12:37:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTgwMSM2OTgyOTA0IzUwMDEyMTE2MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cervomed-announces-new-hire-to-support-neflamapimod-development-and-commercialization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=858956"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858956\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=858956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=858956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=858956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}